A Study of LY900014 Formulations in Healthy Participants: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of LY900014 Formulations in Healthy Participants (NCT02317575), a randomized phase 1 study. The primary outcome is Part A: Pharmacokinetics (PK ): Area Under the Concentration Curve From Zero to the Last Recorded Time Post Dose (AUC0-tlast).

2. Clinical Question

3. Trial Design

This was a completed phase 1 study sponsored by Eli Lilly and Company. The record lists an enrollment of 29 and describes the study as randomized, double-masked, and crossover. It began in 2015-01, with primary completion in 2015-04. Participants were healthy volunteers, rather than people being treated for a condition.

Part A included four LY900014 test formulations and an insulin lispro reference. The reference dose was 15 U; the test-formulation doses are not reported in the registry record. Each treatment was described as a single subcutaneous dose given in one of five periods. The brief summary says injections were administered under the skin of the abdomen. A crossover design means participants can receive multiple treatments across periods, allowing treatment responses to be compared within participants. The exact treatment sequence and period-level procedures are not reported in the registry record.

The study was planned in two parts. Part B would have evaluated a formulation selected from Part A in one of four periods. The registry record states that Part B was not executed because no suitable formulation was identified. Consequently, the posted outcome data concern Part A, not a later evaluation of a selected test formulation.

The primary outcome population is described as participants who received at least 1 dose and completed the dose sequence. Outcome-specific counts are 27 for formulations A, B, and D and the reference, and 28 for formulation C. The reason for these different counts is not reported in the registry record. The study included safety and tolerability assessments, pharmacokinetic measurements, and glucodynamic objectives, although the posted primary outcome is pharmacokinetic exposure.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Part A was a 5-period crossover study of four LY900014 formulations (Tests A, B, C, and D) and insulin lispro (Reference (R)). A minimum of 3 days washout between each period.

Period 1

Reasons for not completing this period:

Period 2

Period 3

Period 4

Analysis population for the primary outcome, as defined in the registry: All participants who received at least 1 dose of study drug and completed the dose sequence.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants who received at least 1 dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Part A: Pharmacokinetics (PK ): Area Under the Concentration Curve From Zero to the Last Recorded Time Post Dose (AUC0-tlast), measured over 30 minutes predose, 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 90, 120, 150, 180, 240, and 300 minutes postdose.

The primary endpoint is the area under the concentration curve from zero to the last recorded time after dosing, abbreviated AUC0-tlast in the registry record. Concentration measurements were scheduled from 30 minutes predose through 300 minutes postdose, at the listed sampling times. The endpoint is expressed in picomol times hour per liter (pmol*h/L).

In general, an area under a concentration-time curve summarizes drug concentration over a defined observation interval. It is used in pharmacokinetic studies as a measure of systemic exposure, combining information across multiple measurements rather than relying on a single concentration at one time. AUC0-tlast is limited to the last recorded concentration measurement; it is not, by definition, the full exposure over an unlimited period.

The registry reports geometric least-squares means and geometric coefficients of variation for each Part A treatment. In general, a geometric summary is useful for measurements that are analyzed on a logarithmic scale, where relative variation and proportional differences can be more meaningful than absolute differences. The registry record does not describe the model or transformation used to obtain these reported summaries, so the details of the statistical estimation cannot be established from the record.

The listed outcome population consists of participants who received at least 1 dose and completed the dose sequence. The record gives the endpoint and summaries but does not report inferential comparisons, confidence intervals, or a clinically meaningful threshold for interpreting differences in exposure.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the study as randomized, double-masked, and crossover. These design features describe how treatments were assigned and how the study was conducted, but they do not by themselves specify the statistical model used for the primary analysis. The registry record does not report a detailed statistical analysis plan, the randomization procedure, or the masking procedures.

What does a crossover design mean?

In general, a crossover design assigns participants to receive more than one treatment in successive periods. Comparisons can then use the fact that the same participant contributes measurements under different treatments, which may help account for stable differences between participants. It also means that treatment outcomes should not automatically be interpreted as independent groups of people. Period effects, sequence effects, and possible carryover are considerations in crossover analyses. The registry record does not report how these considerations were handled, or whether they were assessed.

Part A used five periods and included four LY900014 test formulations and an insulin lispro reference. The record says each single dose was given in one of five periods, but does not provide the treatment sequences, the timing between periods, or the analysis model. Those details are needed to understand precisely how the crossover structure informed the reported estimates.

How should geometric summaries be read?

The primary outcome is reported as a geometric least-squares mean, with a geometric coefficient of variation. In general, a geometric mean summarizes measurements after taking logarithms and then returning the summary to the original measurement scale. A least-squares mean is generally a model-based estimate, but the registry record does not identify the model or its covariates. No particular adjustment or modeling detail should be inferred from the label alone.

In general, concentration and exposure measurements can be right-skewed, and analysis on a logarithmic scale can be useful when proportional differences are of interest. A geometric coefficient of variation is a relative variability summary, rather than a confidence interval or a measure of statistical significance. The registry record supplies no confidence limits for the outcome summaries and no standard errors or participant-level data from which to assess precision independently.

What can be concluded from the posted comparisons?

The posted summaries give one geometric mean and one variability value for each treatment, along with the number of participants contributing to the outcome. They do not report treatment ratios, confidence intervals, p-values, or an inferential test. A visual or numerical ordering of the means is descriptive only. Without the analysis details and uncertainty estimates, the summaries cannot establish whether differences are compatible with chance variation, nor can they establish equivalence.

The record lists five outcome measures and four posted secondary outcomes, but it does not provide analysis results for those secondary outcomes in the information reported. The number of posted analyses is zero. The record also does not state how multiple outcomes or multiple treatment comparisons were addressed. In general, when many outcomes or contrasts are examined, multiplicity procedures may be used to control the chance of false-positive findings; whether any such procedure was planned or used is not reported in the registry record.

What does the planning illustration represent?

In general, a sample-size calculation estimates how many participants would be needed under specified assumptions to detect a target effect with a chosen significance level and power. The stated planning assumptions use a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a fraction of the observed effect. These calculations are planning illustrations based on the observed effect, not the trial's original design justification and not observed power. The registry record does not report the original sample-size justification. No new sample-size calculation can be inferred from the endpoint summaries without additional assumptions and inputs.

The stated assumptions refer to two-arm calculations, while the reported study has multiple treatments in a crossover structure. This is an important distinction: a two-arm planning illustration is not a substitute for the design-specific analysis or for the trial's prospective sample-size rationale. The record does not report whether interim analyses were planned or conducted, what decision thresholds were used, or whether any multiplicity adjustment was specified.

Finally, the registry describes the primary-outcome population as participants who received at least 1 dose and completed the dose sequence. In general, restricting an analysis to participants who completed a sequence can make the analysis population differ from everyone enrolled or randomized. The registry does not give a full participant flow, reasons for noncompletion, or a separate intention-to-treat analysis description, so the consequences of the population definition cannot be assessed from the record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary pharmacokinetic outcome and four secondary outcomes. The secondary outcomes concern injection-site pain measured by a visual analog scale, total glucose infused over the clamp in Part A, interparticipant variability in total glucose infused in Part B, and interparticipant variability in AUC0-tlast in Part B. The brief summary says Part B was not executed because no suitable formulation was identified. Results for those Part B outcomes are therefore not available in the listed record. The registry record does not report a multiplicity strategy for the primary and secondary outcomes or for comparisons among the Part A formulations.

Multiplicity matters in general when a study makes several statistical comparisons: without an appropriate strategy, the chance of at least one false-positive result can increase. The registry record does not state whether outcomes were tested hierarchically, adjusted for multiplicity, or treated as exploratory. It also does not provide inferential results for the primary endpoint. The number of posted analyses is zero, so the record does not show how any multiplicity plan was implemented.

The endpoint population is defined as participants who received at least 1 dose and completed the dose sequence. The registry record does not report a full accounting of enrolled, randomized, treated, and completing participants by sequence, nor reasons for missing observations. It does not describe an imputation method or other handling of missing outcome data. The treatment-specific outcome counts are 27, 27, 28, 27, and 27 for formulations A, B, C, D, and the reference, respectively, but these counts alone do not explain why measurements were unavailable for some participants or periods.

The record does not report an intention-to-treat analysis, a per-protocol analysis beyond the stated outcome population, or sensitivity analyses for missing data. As a result, the potential influence of missing observations and the robustness of the reported summaries cannot be assessed from the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports serious adverse events affecting 0 participants in each of the five Part A treatment groups. The numbers at risk are 27 for formulations A, B, and D and the reference, and 28 for formulation C. No serious adverse event terms are listed. The deaths field is not populated, so deaths are not reported in the registry record.

Other adverse events affected 5 participants for formulation A, 5 for formulation B, 2 for formulation C, 6 for formulation D, and 2 for the reference. These are participant counts, not counts of distinct event types or event episodes. The terms for these other adverse events are not reported in the listed results, so their nature, severity, and timing cannot be described from these figures.

In general, an absence of recorded serious adverse events in a study does not establish that no risk exists. This was a phase 1 study in healthy participants, and the treatment groups reflect a crossover study in which participants could receive different treatments in separate periods. The registry figures should therefore be read as descriptive safety counts within the reported groups, not as independent-group comparisons or as evidence of a causal difference between formulations.

12. What the Result Does, and Does Not, Mean

The results establish that the registry record contains Part A pharmacokinetic summaries for four LY900014 test formulations and an insulin lispro reference. The reported geometric least-squares means range from 1690 for the reference to 1810 for formulation C, with geometric coefficients of variation from 17 to 21 across the five treatments. The record also gives treatment-specific participant counts and adverse-event counts. These are descriptive findings from the posted record.

They do not establish the statistical significance of any treatment comparison. The registry does not report confidence intervals, p-values, treatment ratios, or other inferential comparisons for the primary endpoint. The summaries do not establish equivalence, noninferiority, or superiority. Such conclusions require a defined comparison, an appropriate analysis, and a measure of uncertainty; those results are not reported in the registry record.

The study was conducted in healthy participants, and Part B was not executed because no suitable formulation was identified. These features limit what can be inferred about use in people with a medical condition or about a selected formulation in the planned later part. The primary measure is pharmacokinetic exposure over the observed concentration-sampling interval. It does not, by itself, summarize clinical benefit or long-term safety.

The adverse-event numbers provide counts but not the event terms for the other adverse events. Serious adverse events affected 0 participants in each listed group, but that observation should not be read as proof that serious events cannot occur. The record also does not provide enough analysis detail to determine how crossover features, missing data, or multiple comparisons were handled.

Overall, the posted information describes the outcome summaries and the study's basic structure, while leaving important questions about precision and inferential interpretation unanswered. The figures are useful as a record of what was reported for Part A, but they cannot replace a full statistical analysis or supply conclusions that the registry does not report.

13. Why This Trial Matters Statistically

This study illustrates a common distinction in early clinical research: a trial can report several treatment-specific summaries without reporting the inferential comparisons needed to quantify uncertainty. The primary endpoint is a pharmacokinetic exposure measure, summarized with geometric least-squares means and geometric coefficients of variation. Those statistics describe the posted observations, but do not alone establish how precisely treatments differ.

The crossover structure also matters statistically. In general, crossover studies collect information across more than one treatment period for participants, so observations from the same participant are related. Recognizing that relationship is important when estimating treatment contrasts and their uncertainty. The registry record identifies the design but does not describe the model or how period and sequence effects were handled. This means readers cannot reconstruct the inferential analysis from the posted summaries.

The study's planned two-part structure is another useful feature to note. Part A tested four formulations and a reference; Part B was not conducted because no suitable formulation was identified. Consequently, the record illustrates why planned outcomes and completed outcomes should be distinguished. Outcomes listed for Part B are not results from an executed study part.

Finally, the record shows why descriptive safety counts need context. Counts of participants with serious or other adverse events are not equivalent to a comparative safety analysis, particularly when participants may receive multiple treatments in a crossover study. The absence of reported serious adverse events is a summary of this record, not a general risk estimate.

For biostatistical interpretation, this trial therefore highlights the importance of distinguishing study design, endpoint summaries, uncertainty estimates, analysis populations, multiplicity decisions, and completed versus unexecuted study parts. Several of those elements are not reported in the registry record, which limits the conclusions that can be drawn from its posted results.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record gives treatment-specific geometric least-squares means and geometric coefficients of variation, but does not report confidence intervals, p-values, treatment ratios, or other inferential comparisons for the primary endpoint. The precision of differences between formulations therefore cannot be evaluated from the posted outcome summaries.

Although the trial is identified as randomized, double-masked, and crossover, the registry record does not describe the randomization method, treatment sequences, period spacing, statistical model, covariates, or handling of period and sequence effects. It also does not report whether carryover was assessed. These omissions prevent a detailed evaluation of how the study design was incorporated into the primary analysis.

The primary population is defined as participants who received at least 1 dose and completed the dose sequence. The record does not report full participant flow, reasons for missing data, or sensitivity analyses. Treatment-specific counts range from 27 to 28, but the reasons for this variation are not reported in the registry record.

Part B was not executed because no suitable formulation was identified. Although the record lists secondary outcomes for Part B, those outcomes do not represent completed Part B results. The registry record also does not report the original sample-size justification, a detailed statistical analysis plan, interim analyses, or a strategy for multiplicity.

The study involved healthy participants and its primary outcome was pharmacokinetic exposure. The record does not establish how these results apply to people with a medical condition or to clinical outcomes. Safety results include counts, but the terms for other adverse events are not reported, and the deaths field is not populated.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study of LY900014 Formulations in Healthy Participants — NCT02317575.
• Registry record last updated 2020-05-13; status last verified 2015-09.
• Results first posted 2020-05-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT02317575 is a completed phase 1 study of LY900014 formulations in healthy participants, sponsored by Eli Lilly and Company. The registry lists an enrollment of 29, randomized double-masked crossover design, and dates of 2015-01 to 2015-04 for study start and primary completion.

Part A compared four single-dose LY900014 test formulations with a 15 U insulin lispro reference across five periods. The primary outcome was AUC0-tlast, reported as geometric least-squares means and geometric coefficients of variation. The endpoint population comprised participants who received at least 1 dose and completed the dose sequence. Part B was not executed because no suitable formulation was identified.

The record reports descriptive pharmacokinetic and adverse-event summaries but does not report inferential comparisons or confidence intervals for the primary endpoint. It also does not report a detailed analysis plan, multiplicity strategy, or full missing-data accounting.